ASIT biotech (Euronext: ASIT) has reported positive results from its Phase III clinical trial into gp-ASIT+, resulting in high trading volumes and a 2% spike in the company’s share price today.
The Belgian biopharmaceutical company, which focuses on immunotherapy products for the treatment of allergies, is developing the drug to combat grass pollen rhinitis.
The company reports it is the first ever clinical study to demonstrate the clinical efficacy of allergen peptides in a real-life setting. The trial took place at 67 clinical centers in Europe, and involved 554 randomized patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze